These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8095737)

  • 41. Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects.
    Altshuler LL; Ventura J; van Gorp WG; Green MF; Theberge DC; Mintz J
    Biol Psychiatry; 2004 Oct; 56(8):560-9. PubMed ID: 15476685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lateralisation of cortical function during cognitive tasks: regional cerebral blood flow studies of normal individuals and patients with schizophrenia.
    Berman KF; Weinberger DR
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):150-60. PubMed ID: 2313303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuroleptics, dopamine, and schizophrenia.
    Pickar D
    Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effective connectivity during episodic memory retrieval in schizophrenia participants before and after antipsychotic medication.
    Hutcheson NL; Sreenivasan KR; Deshpande G; Reid MA; Hadley J; White DM; Ver Hoef L; Lahti AC
    Hum Brain Mapp; 2015 Apr; 36(4):1442-57. PubMed ID: 25504918
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Course of schizophrenia: neuropsychological evidence for a static encephalopathy.
    Goldberg TE; Hyde TM; Kleinman JE; Weinberger DR
    Schizophr Bull; 1993; 19(4):797-804. PubMed ID: 8303228
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The neurochemical circuitry of schizophrenia.
    Carlsson A
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S10-4. PubMed ID: 16508890
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Symptom dimensions of schizophrenia: a selective integration of neurophysiological and neuropsychological correlates.
    Aderibigbe YA; Gureje O
    Neuropsychobiology; 1996; 34(4):192-200. PubMed ID: 9121620
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Developmentally moderated expressions of the neuropathology underlying schizophrenia.
    Walker EF
    Schizophr Bull; 1994; 20(3):453-80. PubMed ID: 7526447
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The neuropsychology of schizophrenia: a neurodevelopmental and case study approach.
    Seidman LJ
    J Neuropsychiatry Clin Neurosci; 1990; 2(3):301-12. PubMed ID: 2136090
    [No Abstract]   [Full Text] [Related]  

  • 50. Auditory mismatch impairments are characterized by core neural dysfunctions in schizophrenia.
    Gaebler AJ; Mathiak K; Koten JW; König AA; Koush Y; Weyer D; Depner C; Matentzoglu S; Edgar JC; Willmes K; Zvyagintsev M
    Brain; 2015 May; 138(Pt 5):1410-23. PubMed ID: 25743635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Abnormal neural integration related to cognition in schizophrenia.
    Dolan RJ; Fletcher PC; McKenna P; Friston KJ; Frith CD
    Acta Psychiatr Scand Suppl; 1999; 395():58-67. PubMed ID: 10225334
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blink rate, neurocognitive impairments, and symptoms in schizophrenia.
    Chen EY; Lam LC; Chen RY; Nguyen DG
    Biol Psychiatry; 1996 Oct; 40(7):597-603. PubMed ID: 8886292
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dopamine and norepinephrine activity in schizophrenia. An integrative perspective.
    van Kammen DP; Kelley M
    Schizophr Res; 1991; 4(2):173-91. PubMed ID: 2039760
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in neurocognitive functioning during transition to manifest disease: comparison of individuals at risk for schizophrenic and bipolar affective psychoses.
    Metzler S; Dvorsky D; Wyss C; Müller M; Gerstenberg M; Traber-Walker N; Walitza S; Theodoridou A; Rössler W; Heekeren K
    Psychol Med; 2015 Jul; 45(10):2123-34. PubMed ID: 25640248
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Event-related potentials (ERPs) as indicators of risk for schizophrenia.
    Friedman D; Squires-Wheeler E
    Schizophr Bull; 1994; 20(1):63-74. PubMed ID: 8197422
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Smoking and schizophrenia.
    Sagud M; Mihaljević-Peles A; Mück-Seler D; Pivac N; Vuksan-Cusa B; Brataljenović T; Jakovljević M
    Psychiatr Danub; 2009 Sep; 21(3):371-5. PubMed ID: 19794359
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of clozapine on cognitive function in schizophrenia.
    Lee MA; Thompson PA; Meltzer HY
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():82-7. PubMed ID: 7961582
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of risperidone on cognition in patients with schizophrenia.
    Stip E; Lussier I
    Can J Psychiatry; 1996 Oct; 41(8 Suppl 2):S35-40. PubMed ID: 8899249
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neurodevelopmental model of schizophrenia.
    Feinberg I
    Biol Psychiatry; 1992 Jul; 32(2):212-3. PubMed ID: 1420639
    [No Abstract]   [Full Text] [Related]  

  • 60. The role of dopamine for the pathophysiology of schizophrenia.
    Meisenzahl EM; Schmitt GJ; Scheuerecker J; Möller HJ
    Int Rev Psychiatry; 2007 Aug; 19(4):337-45. PubMed ID: 17671867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.